Citadel Advisors
NPCE icon

Citadel Advisors’s Neuropace NPCE Stock Holding History

Citadel Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
128,800
+41,516
+48% +$668K ﹤0.01% 6498
2026
Q1 		$1.15M Sell
87,284
-44,575
-34% -$669K ﹤0.01% 7342
2025
Q4 		$2.04M Buy
+131,859
New +$1.76M ﹤0.01% 5865
2025
Q2 		– Sell
-123,346
Closed -$1.54M – 14238
2025
Q1 		$1.52M Buy
123,346
+84,739
+219% +$1.06M ﹤0.01% 6078
2024
Q4 		$432K Buy
38,607
+22,126
+134% +$192K ﹤0.01% 8886
2024
Q3 		$115K Sell
16,481
-20,631
-56% -$151K ﹤0.01% 10933
2024
Q2 		$281K Buy
37,112
+28,962
+355% +$292K ﹤0.01% 9272
2024
Q1 		$108K Sell
8,150
-15,905
-66% -$227K ﹤0.01% 11255
2023
Q4 		$248K Buy
+24,055
New +$192K ﹤0.01% 9538
2022
Q3 		– Sell
-21,692
Closed -$108K – 13272
2022
Q2 		$108K Buy
+21,692
New +$143K ﹤0.01% 11337
2022
Q1 		– Sell
-10,009
Closed -$101K – 14256
2021
Q4 		$101K Sell
10,009
-15,813
-61% -$205K ﹤0.01% 12717
2021
Q3 		$410K Buy
+25,822
New +$542K ﹤0.01% 10353

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors's NPCE Position: Q2 2026 in Review

Citadel Advisors increased its Neuropace (NPCE) stake by 48% in Q2 2026, buying an estimated $668K and bringing the position to 128,800 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #6498.

Citadel Advisors first reported a position in NPCE in Q3 2021 and has held it in 12 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Citadel Advisors held 128,800 shares of Neuropace worth $2.05M as of Q2 2026.
  • Citadel Advisors bought 41,516 Neuropace shares in Q2 2026, an estimated $668K.
  • Neuropace made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6498 holding.
  • Citadel Advisors first reported a position in Neuropace in Q3 2021 and has held it in 12 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.